NASDAQ
CPRX

Catalyst Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Catalyst Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$12.6104
Today's High:
$13.07
Open Price:
$12.78
52W Low:
$6.15
52W High:
$22.11
Prev. Close:
$12.78
Volume:
971846

Company Statistics

Market Cap.:
$1.22 billion
Book Value:
3.15
Revenue TTM:
$256.48 million
Operating Margin TTM:
46.82%
Gross Profit TTM:
$160.02 million
Profit Margin:
38.76%
Return on Assets TTM:
22.94%
Return on Equity TTM:
35.89%

Company Profile

Catalyst Pharmaceuticals Inc had its IPO on 2006-11-08 under the ticker symbol CPRX.

The company operates in the Healthcare sector and Biotechnology industry. Catalyst Pharmaceuticals Inc has a staff strength of 82 employees.

Stock update

Shares of Catalyst Pharmaceuticals Inc opened at $12.78 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $12.61 - $13.07, and closed at $12.93.

This is a +1.17% increase from the previous day's closing price.

A total volume of 971,846 shares were traded at the close of the day’s session.

In the last one week, shares of Catalyst Pharmaceuticals Inc have slipped by -7.11%.

Catalyst Pharmaceuticals Inc's Key Ratios

Catalyst Pharmaceuticals Inc has a market cap of $1.22 billion, indicating a price to book ratio of 6.4746 and a price to sales ratio of 9.1396.

In the last 12-months Catalyst Pharmaceuticals Inc’s revenue was $256.48 million with a gross profit of $160.02 million and an EBITDA of $127.89 million. The EBITDA ratio measures Catalyst Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Catalyst Pharmaceuticals Inc’s operating margin was 46.82% while its return on assets stood at 22.94% with a return of equity of 35.89%.

In Q1, Catalyst Pharmaceuticals Inc’s quarterly earnings growth was a positive 116.7% while revenue growth was a positive 98.1%.

Catalyst Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
19.305
Trailing PE
12.9663
PEG
0

Its diluted EPS in the last 12-months stands at $0.89 per share while it has a forward price to earnings multiple of 19.305 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Catalyst Pharmaceuticals Inc’s profitability.

Catalyst Pharmaceuticals Inc stock is trading at a EV to sales ratio of 7.8032 and a EV to EBITDA ratio of 17.7212. Its price to sales ratio in the trailing 12-months stood at 9.1396.

Catalyst Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$407.23 million
Total Liabilities
$56.71 million
Operating Cash Flow
$-162367000.00
Capital Expenditure
$74000
Dividend Payout Ratio
0%

Catalyst Pharmaceuticals Inc ended 2024 with $407.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $407.23 million while shareholder equity stood at $333.66 million.

Catalyst Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $56.71 million in other current liabilities, 106000.00 in common stock, $79.43 million in retained earnings and $0 in goodwill. Its cash balance stood at $148.25 million and cash and short-term investments were $148.25 million. The company’s total short-term debt was $345,000 while long-term debt stood at $0.

Catalyst Pharmaceuticals Inc’s total current assets stands at $198.91 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $33.40 million compared to accounts payable of $3.39 million and inventory worth $10.33 million.

In 2024, Catalyst Pharmaceuticals Inc's operating cash flow was $-162367000.00 while its capital expenditure stood at $74000.

Comparatively, Catalyst Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$12.93
52-Week High
$22.11
52-Week Low
$6.15
Analyst Target Price
$21.4

Catalyst Pharmaceuticals Inc stock is currently trading at $12.93 per share. It touched a 52-week high of $22.11 and a 52-week low of $22.11. Analysts tracking the stock have a 12-month average target price of $21.4.

Its 50-day moving average was $13.66 and 200-day moving average was $15.26 The short ratio stood at 4.61 indicating a short percent outstanding of 0%.

Around 594.6% of the company’s stock are held by insiders while 8271.6% are held by institutions.

Frequently Asked Questions About Catalyst Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Catalyst Pharmaceuticals Inc is CPRX

The IPO of Catalyst Pharmaceuticals Inc took place on 2006-11-08

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$199.78
2.48
+1.26%
$0.4
0
0%
Sysmex Corp (SSMXY)
$25.89
-0.16
-0.61%
$54.6
1.07
+2%
$16.16
-0.69
-4.1%
$621.01
-8.38
-1.33%
$0.01
0
+6%
$9.85
0
0%
$0.94
0.01
+1.08%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Address

355 Alhambra Circle, Coral Gables, FL, United States, 33134